MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
Integra LifeSciences Holdings Corporation Long-Term Debt 2011-2025 | IART
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Integra LifeSciences Holdings Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 760 M | 570 M | 567 M | 564 M | 1.41 B | 1.3 B | 1.33 B | 1.78 B | 665 M | 701 M | 626 M | 392 M | 520 M | 532 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.78 B | 392 M | 837 M |
Quarterly Long-Term Debt Integra LifeSciences Holdings Corporation
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 746 M | 756 M | 765 M | 770 M | 775 M | 775 M | 775 M | 775 M | 567 M | 810 M | - | 832 M | 564 M | 855 M | 866 M | 878 M | 878 M | 878 M | 878 M | 878 M | 878 M | 889 M | 900 M | 900 M | 900 M | 900 M | 900 M | 1.18 B | - | - | - | - | - | 225 M | 223 M | 221 M | 218 M | 218 M | 218 M | 218 M | 213 M | 213 M | 213 M | 213 M | 205 M | 205 M | 205 M | 205 M | 198 M | 198 M | 198 M | 198 M | 353 M | 353 M | 353 M | 353 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.18 B | 198 M | 558 M |
Long-Term Debt of other stocks in the Medical devices industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
GenMark Diagnostics, Inc.
GNMK
|
71.3 M | - | - | $ 1.77 B |  USA |
 |
Abiomed
ABMD
|
3.66 M | - | - | $ 17.2 B | USA |
 |
Acutus Medical
AFIB
|
32.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Apyx Medical Corporation
APYX
|
33.2 M | $ 3.82 | -1.04 % | $ 132 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
430 K | - | -5.86 % | $ 30.6 M | USA |
 |
Bio-Rad Laboratories
BIO
|
1.2 B | $ 307.08 | -0.33 % | $ 8.66 B | USA |
 |
Apollo Endosurgery
APEN
|
34 M | - | - | $ 475 M | USA |
 |
BioSig Technologies
BSGM
|
103 K | - | 37.08 % | $ 85.7 M | USA |
 |
Bruker Corporation
BRKR
|
2.06 B | $ 45.69 | 1.24 % | $ 6.81 K | USA |
 |
Allied Healthcare Products
AHPI
|
2.93 K | - | 3.58 % | $ 2.21 M | USA |
 |
Abbott Laboratories
ABT
|
12.6 B | $ 128.67 | 2.55 % | $ 224 B | USA |
 |
Boston Scientific Corporation
BSX
|
8.97 B | $ 91.95 | -0.67 % | $ 135 B | USA |
 |
Conformis
CFMS
|
20.6 M | - | - | $ 16.4 M | USA |
 |
CryoLife, Inc.
CRY
|
290 M | - | -4.14 % | $ 702 M | USA |
 |
EDAP TMS S.A.
EDAP
|
2.16 M | $ 3.18 | 10.56 % | $ 119 M |  France |
 |
Cardiovascular Systems
CSII
|
1.33 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
1.06 M | - | -10.19 % | $ 1.99 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
154 K | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
38.6 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
7.64 M | - | - | $ 111 M |  Canada |
 |
Eargo
EAR
|
11.9 M | - | - | $ 10.2 M | USA |
 |
Dynatronics Corporation
DYNT
|
1.11 M | - | 14.99 % | $ 929 K | USA |
 |
Intersect ENT, Inc.
XENT
|
63.6 M | - | - | $ 955 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
24.1 M | $ 9.58 | -2.84 % | $ 688 M | Israel |
 |
IRIDEX Corporation
IRIX
|
1.75 M | $ 0.99 | 7.52 % | $ 16 M | USA |
 |
IRadimed Corporation
IRMD
|
1.42 K | $ 96.99 | 0.79 % | $ 1.23 B | USA |
 |
Second Sight Medical Products
EYES
|
18 M | - | -0.97 % | $ 54.4 M | USA |
 |
Align Technology
ALGN
|
88.2 M | $ 163.04 | -1.44 % | $ 12.2 B | USA |
 |
Accuray Incorporated
ARAY
|
124 M | $ 1.04 | -2.06 % | $ 107 M | USA |
 |
Avinger
AVGR
|
1.1 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
3.01 M | $ 12.5 | -1.66 % | $ 338 M | USA |
 |
FONAR Corporation
FONR
|
155 K | $ 14.9 | 0.99 % | $ 97.7 M | USA |
 |
AxoGen
AXGN
|
47.5 M | $ 30.0 | -1.3 % | $ 1.33 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
7.56 M | - | - | $ 3.31 B | USA |
 |
GBS
GBS
|
1.65 M | - | -0.57 % | $ 7.12 M | USA |
 |
CONMED Corporation
CNMD
|
905 M | $ 40.3 | -1.29 % | $ 1.24 B | USA |
 |
LivaNova PLC
LIVN
|
550 M | $ 63.28 | 0.84 % | $ 3.43 B |  Britain |
 |
OrthoPediatrics Corp.
KIDS
|
73 M | $ 17.83 | 1.31 % | $ 411 M | USA |
 |
Globus Medical
GMED
|
298 K | $ 86.73 | 0.05 % | $ 11.8 B | USA |
|
LENSAR
LNSR
|
2.09 M | $ 11.51 | -0.04 % | $ 133 M | USA |
 |
Aziyo Biologics
AZYO
|
20.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Alphatec Holdings
ATEC
|
575 M | $ 19.79 | -0.85 % | $ 2.83 B | USA |
 |
Aethlon Medical
AEMD
|
337 K | $ 3.07 | -9.71 % | $ 4.79 M | USA |
 |
Establishment Labs Holdings
ESTA
|
220 M | $ 72.39 | -0.17 % | $ 2.04 B |  Costa-rica |